Shares of Neos Therapeutics Inc (NASDAQ:NEOS) have earned a consensus broker rating score of 1.50 (Buy) from the two analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and one has issued a strong buy rating on the company.
Brokerages have set a 12-month consensus price target of $32.50 for the company, according to Zacks. Zacks has also assigned Neos Therapeutics an industry rank of 61 out of 265 based on the ratings given to its competitors.
Neos Therapeutics (NASDAQ:NEOS) opened at 14.32 on Monday. Neos Therapeutics has a 52-week low of $11.53 and a 52-week high of $28.99. The firm’s market cap is $228.29 million. The company has a 50 day moving average price of $14.31 and a 200-day moving average price of $18.10.
A number of equities analysts have commented on the company. RBC Capital reduced their price objective on Neos Therapeutics from $35.00 to $33.00 and set an “outperform” rating on the stock in a research note on Thursday, November 12th. JMP Securities boosted their price objective on Neos Therapeutics to $33.00 and gave the stock a “market outperform” rating in a research note on Thursday, November 12th.
Neos Therapeutics, Inc. is a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (NASDAQ:NEOS) using its drug delivery technologies. The Company’s product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. It manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD, and NT-0201 amphetamine XR liquid suspension for the treatment of ADHD. The company is headquartered in Grand Prairie, Texas.
For more information about research offerings from Zacks Investment Research, visit Zacks.com